Cyclopharm (ASX:CYC) Retained Earnings: A$-65.08 Mil (As of Dec. 2025)


ASX:CYC Cyclopharm Ltd ASX:CYC
45 GF Score
Price A$0.53
GF Value A$0.83
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Cyclopharm Retained Earnings?

Cyclopharm ASX:CYC +2.94% 45 Retained Earnings is A$-65.08 Mil as of Dec. 2025. GuruFocus rates ASX:CYC with a GF Score™ of 45/100 and a GF Value™ of A$0.83 (Possible Value Trap). The stock has 7 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Cyclopharm's retained earnings for the quarter that ended in Dec. 2025 was A$-65.08 Mil.

Cyclopharm's quarterly retained earnings declined from Dec. 2024 (A$-47.86 Mil) to Jun. 2025 (A$-55.54 Mil) and declined from Jun. 2025 (A$-55.54 Mil) to Dec. 2025 (A$-65.08 Mil).

Cyclopharm's annual retained earnings declined from Dec. 2023 (A$-34.66 Mil) to Dec. 2024 (A$-47.86 Mil) and declined from Dec. 2024 (A$-47.86 Mil) to Dec. 2025 (A$-65.08 Mil).


Cyclopharm  (ASX:CYC) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Cyclopharm Retained Earnings Historical Data

* Premium members only.

The historical data trend for Cyclopharm's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyclopharm Retained Earnings Chart

Cyclopharm Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -21.58 -29.07 -34.66 -47.86 -65.08

Cyclopharm Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -34.66 -42.17 -47.86 -55.54 -65.08
ASX:CYC
45GF Score
Cyclopharm Ltd ASX:CYC
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cyclopharm Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of A$-65.08 Mil mean?
Cyclopharm (ASX:CYC) has a Retained Earnings of A$-65.08 Mil as of Dec. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on Cyclopharm and its competitors.
Is Cyclopharm's Retained Earnings too high?
Cyclopharm's current Retained Earnings is A$-65.08 Mil. Overall, Cyclopharm has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyclopharm's Retained Earnings compare to MCK and CAH?
Cyclopharm's Retained Earnings of A$-65.08 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Medical Distribution company?
A good Retained Earnings depends on the Medical Distribution industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Cyclopharm and its competitors. Cyclopharm's current Retained Earnings is A$-65.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyclopharm stock overvalued right now?
Based on GuruFocus' analysis, Cyclopharm (ASX:CYC) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.83, compared to a current price of A$0.53 — trading 36.7% below its estimated fair value. The current Retained Earnings is A$-65.08 Mil. Cyclopharm's overall GF Score™ is 45/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Cyclopharm (ASX:CYC), the current Retained Earnings is A$-65.08 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cyclopharm (ASX:CYC) Overvalued in 2026?

Based on GuruFocus' analysis, Cyclopharm stock appears to be undervalued. The current stock price of A$0.53 is trading 36.7% below its estimated GF Value™ of A$0.83. GuruFocus considers Cyclopharm to be Possible Value Trap.

Key valuation signals for ASX:CYC:

  • Retained Earnings: A$-65.08 Mil
  • GF Value™: A$0.83 vs. price of A$0.53 (36.7% below fair value)
  • GF Score™: 45/100 with 7 warning signs

No single metric tells the full story. See the ASX:CYC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cyclopharm Business Description

Address 1 The Crescent, Unit 4, Kingsgrove, Sydney, NSW, AUS, 2208
Cyclopharm Ltd is a health technology company offering solutions related to functional lung ventilation imaging. Its proprietary product Technegas is a broad-spectrum diagnostic lung imaging technology product for the visualisation of pulmonary ventilation and lung function. The company sells its products to healthcare institutions and medical professionals. Maximum revenue is generated from its Technegas products and services, which include the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. Geographically, the company generates maximum revenue from its business in Europe, and the rest from Asia Pacific, Canada, the USA, and other regions.
45GF Score

Get the complete analysis for ASX:CYC

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.53
Price
A$0.83
GF Value